On June 21, 2022 Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, reported the Company will host a hybrid webcast to discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC) presented earlier that day in a late-breaking oral presentation at the ESMO (Free ESMO Whitepaper) World Congress on Gastrointestinal Cancer in Barcelona, Spain (Press release, Agenus, JUN 21, 2022, View Source [SID1234616137]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webcast will take place on Wednesday, June 29 at 10:00 AM EST (4:00 PM local time) and will include the following speakers:
Steven O’Day, M.D., Agenus’ Chief Medical Officer,
Dr. Anthony El-Khoueiry, M.D., Phase I Program Director at the USC Norris Comprehensive Cancer Center, Keck Medicine of USC,
Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital, and
Dr. Heinz-Josef Lenz, M.D., Professor of Medicine and J. Terrence Lanni Chair in Gastrointestinal Cancer Research, Keck Medicine of USC
Formal remarks will be followed by a Q&A session. For those attending in person, the webcast will take place at:
AC Hotel by Marriott Barcelona Forum
Gracia Room (3rd Fl.)
Paseo Taulat 278
Barcelona, Spain, 08019
Registration for the webcast can be accessed on the Investors section of the Agenus website at investor.agenusbio.com, as well as here. Following the webcast, an archived version will also be available on the website.